VolitionRx Limited (NYSE American: VNRX) announced the submission of a clinical manuscript for peer review demonstrating high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The study reported 97% specificity and identified 86% of lymphoma cases, marking significant progress in developing a blood-based liquid biopsy test for feline cancer.
The company emphasized that the technology addresses a substantial unmet need in veterinary medicine and represents a notable commercial opportunity. VolitionRx expects that publication of the study in a peer-reviewed journal will trigger a $5 million contractual milestone payment, advancing its path toward product commercialization and strengthening its presence in the growing companion animal oncology market.
VolitionRx is a multinational company focused on advancing epigenetics. Through its subsidiaries, it develops and commercializes simple, cost-effective blood tests for early detection and monitoring of diseases, including certain cancers and conditions associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with additional offices in the U.S. and London.
The feline cancer test is part of VolitionRx's Nu.Q Vet platform, which aims to provide veterinarians with non-invasive diagnostic tools. The high specificity and sensitivity reported in the study suggest the test could reliably identify cats with lymphoma while minimizing false positives, potentially improving treatment outcomes and quality of life for affected animals.
According to the company, the companion animal oncology market is expanding as pet owners increasingly seek advanced medical care for their animals. A blood-based test for feline lymphoma could offer a simpler, less stressful alternative to traditional diagnostic methods such as tissue biopsies, which require anesthesia and invasive procedures.
The $5 million milestone payment tied to peer-reviewed publication underscores the value VolitionRx places on clinical validation. Such payments are common in the diagnostics industry, providing funding to support further development and commercialization efforts. The company has not disclosed the timeline for publication but noted the manuscript is currently under review.
For further information, visit the company’s website at www.Volition.com.
